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ABSTRACT: Worldwide, cancer is the second leading cause of death.
Regardless of the continuous progress in medicine, we still do not have a fully
effective anti-cancer therapy. Therefore, the search for new targeted anti-
cancer drugs is still an unmet need. Here, we present novel protein−drug
conjugates that inhibit tumor growth in a mouse model of human breast
cancer. We developed conjugates based on fibroblast growth factor (FGF2)
with improved biophysical and biological properties for the efficient killing of
cancer cells overproducing fibroblast growth factor receptor 1 (FGFR1). We
used hydrophilic and biocompatible PEG4 or PEG27 molecules as a spacer between FGF2 and the toxic agent monomethyl
auristatin E. All conjugates exhibited a cytotoxic effect on FGFR1-positive cancer cell lines. The conjugate with the highest
hydrodynamic size (42 kDa) and cytotoxicity was found to efficiently inhibit tumor growth in a mouse model of human breast
cancer.
■ INTRODUCTION
Cancer treatment is one of the major areas of research in
current medicine. Nevertheless, only a limited number of
chemotherapeutics are available for treatment, and even fewer
show significant clinical benefits.1−4 Therefore, the search for
new anticancer therapies is an ever-present need, and targeted
therapy is a promising approach that can meet these
expectations. One of the main strategies in targeted therapy
is the use of antibody−drug conjugates (ADCs). In ADC, a
monoclonal antibody (mAb), as a targeting molecule, is
conjugated to a highly potent cytotoxic drug that kills cancer
cells. Recently, only a few ADCs, including ado-trastuzumab
emtansine (T-DM1, Kadcyla), brentuximab vedotin (Adcet-
ris), gemtuzumab ozogamicin (Mylotarg), inotuzumab ozoga-
micin (Besponsa), and polatuzumab vedotin-piiq (Polivy),
have been approved for treatment by the FDA.5−8 This shows
that despite the high potential of this strategy, further studies
are needed. One possible way forward for such an approach is
to use proteins other than monoclonal antibodies as targeting
molecules.
Previously, we have shown that fibroblast growth factors 1
and 2 (FGF1 and FGF2) are suitable targeting molecules for
killing cancer cells overproducing fibroblast growth factor
receptor 1 (FGFR1).9−17 FGFR1 is a transmembrane protein
that plays a substantial role in regulating cell proliferation,
survival, differentiation, migration, and angiogenesis.18−23
Analyses have shown that 7.1% of all cancer types are
associated with aberration of the FGF-FGFR pathway, with
FGFR1 being the most commonly affected.24,25 Upregulation
of FGFR1 occurs in many types of tumors, including bladder,
breast, lungs, multiple myeloma, pancreatic, prostate, and
various sarcomas.18,21,25−32 Furthermore, overexpression of
FGFR1 is correlated with poor prognosis.33,34 Thus, the
development of therapy based on FGF2 conjugates targeting
FGFR1 is most warranted. FGF2, however, is a relatively small
protein (17.2 kDa), which does not have adequate
pharmacokinetic properties. Therefore, modifications that
increase the effective size and in vivo stability, thereby
prolonging the systemic half-life of the therapeutic macro-
molecule, are required. The widely applied approaches use
PEGylation, PASylation, and conjugation to other proteins,
such as albumin.35−37 PEGylation is a particularly preferred
and common method as it significantly improves solubility and
hydrodynamic radius and reduces immunogenicity, sensibility
to proteolysis, and renal elimination.38−40 It should be noted,
however, that in many cases PEGylation reduces the affinity to
the molecular target.41,42
Here, we developed FGF2-based conjugates with improved
biophysical and biological properties by applying a site- and
stoichiometric-controlled conjugation of PEGylated mono-
methyl auristatin E (MMAE) to FGF2. PEGylation does not
impair the biological activities of the FGF2 conjugate, such as
affinity to the molecular target (FGFR1), and the ability to
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activate FGF-induced signaling and to be internalized by the
receptor-dependent pathway. Taken together, the presented
conjugates have increased hydrophilicity and a larger hydro-
dynamic size, compared to non-PEGylated constructs. Of
outmost importance, they exhibit high toxicity against FGFR1-
overproducing cancer cells in vitro and show efficient tumor
growth retardation in an FGFR-positive human breast cancer
xenograft model in mice.
■ EXPERIMENTAL SECTION
Materials. Reagents and Antibodies. All chemical reagents were
obtained from commercial suppliers and were used without further
purification. L-Cysteine was purchased from BioShop (Burlington,
ON). mc-vc-PAB-MMAE (HY-15575) and monomethyl auristatin E
(HY-15162) were obtained from MedChemExpress (Monmouth
Junction, NJ). mal-dPEG(4)-NHS (PEG1575), mal-dPEG(24)-NHS
(PEG1565), N,N-diisopropylethylamine (DIPEA), and trifluoroacetic
acid (TFA) were purchased from Iris Biotech GmbH (Marktredwitz,
Germany). High-performance liquid chromatography (HPLC)-pure
acetonitrile was purchased from Avantor (Gliwice, Poland), and N,N-
dimethylacetamide (DMAc) was obtained from Sigma-Aldrich
(Merck KGaA, Darmstadt, Germany). The chromatographic columns
HiTrap Desalting with Sephadex G-25 resin, Superdex 75 10/300 GL,
HiTrap CM Sepharose FF, and HiTrap Heparin HP were obtained
from GE Healthcare (UK). Zeba spin desalting columns were
obtained from Thermo Fisher Scientific (Waltham, MA), and Aeris
PEPTIDE 3.6 μm XB-C18 250 × 4.6 mm and Synergi 4 μm Fusion-
RP 80 Å 250 × 10 mm LC columns were obtained from Phenomenex
Inc. (Torrance, CA).
The following antibodies were used: mouse anti-phospho-FGF
Receptor (Tyr653/654) (#3476), rabbit anti-FGF Receptor 1
(#9740), rabbit anti-p44/42 MAPK (#9102), and mouse anti-
phospho-p44/42 MAPK (Thr202/Tyr204) (#9106) from Cell
Signaling Technology (Danvers, MA), mouse anti-γ-tubulin
(T6557) from Sigma-Aldrich (St. Louis, MO), goat anti-FGF2
antibody (sc1390) from Santa Cruz Biotechnology (Dallas, TX),
rabbit anti-FGFR1(ab76464) from Abcam (UK), mouse anti-EEA1
(early endosomal antigen protein-1, #610456) from BD Transduction
Laboratories (San Jose, CA), and goat anti-mouse (115-035-003),
anti-rabbit (111-035-144) conjugated to HRP, and donkey anti-goat,
anti-rabbit, and anti-mouse coupled to the fluorophores Alexa Fluor-
488, Alexa Fluor-568, or Alexa Fluor-647 were obtained from Jackson
ImmunoResearch Europe Ltd. (UK). Annexin V-FITC apoptosis
detection kit was obtained from Thermo Fisher Scientific (Waltham,
MA). All other reagents were obtained from Sigma-Aldrich (Saint
Louis, MO), Thermo Fisher Scientific (Waltham, MA), or BioShop
Canada Inc. (Burlington, ON).
Cells. DMS114 cells (human small cell lung cancer, ATCC CRL-
2066) obtained from American Type Culture Collection (Manassas,
VA) were cultured in the Waymouth’s MB 752/1 medium from
Gibco (Waltham, MA). MCF7 cells (human adenocarcinoma, ATCC
HTB-22) obtained from American Type Culture Collection were
cultured in DMEM high glucose with stable glutamine and sodium
pyruvate from Biowest (France). The MCF7 cells stably expressing
FGFR1 (MCF7-R1) were generated by transfection of pcDNA3-
FGFR1 using DOTAP (Roche Diagnostics). Clones were selected
with 1 mg/mL G-418 and chosen based on their receptor expression
level analyzed by immunofluorescence and immunoblotting. MCF7-
R1 cells were cultured in DMEM high glucose (Biowest) with 50 μg/
mL gentamicin sulfate (Thermo Fisher Scientific), stable glutamine,
and sodium pyruvate (Biowest).
Methods. Synthesis of PEGylated MMAE Moieties. Step 1
Synthesis and Purification of L-Cys-MMAE. L-Cysteine (184 mg, 1.52
mmol, 20 equiv), maleimidocaproyl-valine-citrulline-p-aminobenzoy-
loxycarbonyl-monomethyl auristatin E (100 mg, 0.08 mmol), and
DIPEA (26.5 μL, 0.16 mmol, 2 equiv) were added to 1 mL of DMAc.
The reaction was conducted at 30 °C for 12 h. Next, the solvent was
removed under vacuum. The crude product was dissolved in 500 μL
of 30% acetonitrile/water with 0.1% TFA, and then the final product
was separated from excess of Cys by reversed-phase (RP)-HPLC.
Next, the solvent was removed by lyophilization.
Step 2aSynthesis and Purification of Maleimide-PEG4-MMAE.
To a solution of L-Cys-MMAE (50 mg, 0.035 mmol) in 500 μL of
DMAc was added mal-dPEG(4)-NHS (89.9 mg, 0.175 mmol, 5
equiv) and DIPEA (12.4 μL, 0.075 mmol, 2 equiv). The reaction
mixture was incubated at 30 °C for 12 h. Next, the solvent was
removed under vacuum. The crude product was dissolved in 500 μL
of 30% acetonitrile/water with 0.1% TFA, and then the final product
was separated from excess of Cys by RP-HPLC followed by solvent
removal by lyophilization.
Step 2bSynthesis and Purification of Maleimide-PEG27-
MMAE. To a solution of L-Cys-MMAE (50 mg, 0.035 mmol) in
500 μL of DMAc was added mal-dPEG(27)-NHS (274.8 mg, 0.175
mmol, 5 equiv) and DIPEA (12.4 μL, 0.075 mmol, 2 equiv). The
reaction mixture was incubated at 30 °C for 12 h. Next, the solvent
was removed under vacuum. The crude product was dissolved in 500
μL of 30% acetonitrile/water with 0.1% TFA, and then the final
product was separated from excess of Cys by RP-HPLC. Next, the
solvent was removed by lyophilization.
Protein Production and Purification. The pET-3c plasmid
encoding fibroblast growth factor 2 with N-terminal KCKSGG and
the E. coli Rosetta 2(DE3)pLysS expression strain from Novagen-
EMD Biosciences (Madison, WI) were used to express the
recombinant protein.12 Protein production was carried out in the
BIOSTAT C fermentor system (B. Braun Biotech International,
Germany). Bacteria were grown to OD600 = 8 in a TB medium with
100 μg/mL ampicillin at 37 °C, pO2 = 35−50%, and a stirring speed
of 250 rpm. Then, the temperature was decreased to 20 °C, and the
protein production was induced by adding IPTG to a final
concentration of 0.5 mM and continued for 12 h. After this time,
bacteria were harvested by centrifugation at 6500 g, resuspended in a
lysis buffer (50 mM monosodium phosphate, 0.15 M NaCl, 1 mM
dithiothreitol (DTT), 1 mM ethylenediaminetetraacetic acid
(EDTA), 0.1% Triton X-100, 1 mM PMSF, pH 7.2) supplemented
with 500 U/L of Pierce Universal Nuclease (Thermo Fisher
Scientific), and homogenized using a French press. The cell debris
was separated by ultracentrifugation at 50,000 g at 4 °C for 1 h. The
clarified cell lysate was diluted in 50 mM monosodium phosphate, 0.7
M NaCl, 10 mM (NH4)2SO4, 1 mM DTT, 1 mM EDTA, pH 7.2 and
loaded on a HiTrap Heparin HP column. The column was washed
with a washing buffer (50 mM monosodium phosphate, 1.0 M NaCl,
10 mM (NH4)2SO4, 1 mM DTT, 1 mM EDTA, pH 7.2), and proteins
were eluted with a linear 1.0−2.0 M gradient of NaCl in the same
buffer.
Conjugation of MMAE and PEGylated MMAEs to FGF2.
MMAE, maleimide-PEG4-MMAE, and maleimide-PEG27-MMAE
were dissolved in DMAc at a concentration of 50 mg/mL. Attachment
of a cytotoxic payload containing a maleimide moiety to the sulfhydryl
group of the protein was performed in the reaction buffer (25 mM
monosodium phosphate, 10 mM Na2SO4, 10 mM methionine, 1 mM
EDTA, pH 7.0) at a protein concentration of 0.5 mg/mL and fivefold
molar excess of payload per sulfhydryl group. The reaction was
performed at 20 °C for 1 h. The conjugates were then purified using
the HiTrap CM Sepharose column. The reaction mixtures were
loaded onto the column, the unreacted payload was washed with 25
mM monosodium phosphate and 10 mM Na2SO4, and finally the
conjugates were eluted with the same buffer containing 0.5 M NaCl.
RP-HPLC. To evaluate the conjugation yield and homogeneity of
products, the RP-HPLC analysis was performed using the 1260
Infinity Nanoflow LC system (Agilent Technologies, CA) and a C18
column (Aeris PEPTIDE 3.6 μm XB-C18 250 × 4.6 mm,
Phenomenex Inc., Torrance, CA) with 35−45% gradient of water−
acetonitrile supplemented with 0.1% TFA. Absorption measurements
at 280 nm were used to detect the conjugates.
Mass Spectrometry (MS). The molecular masses of protein and
conjugates were determined by matrix-assisted laser desorption/
ionization−time-of-flight−mass spectrometry (MALDI-TOF-MS, AB
4800+, Applied Biosystems, Waltham, MA) using α-cyano-4-
hydroxycinnamic acid as the matrix.
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Spectrofluorimetry. To validate the folded state of the protein
and conjugates, spectrofluorimetric measurements were performed.
Fluorescence spectra were acquired using an FP-8500 spectrofluorim-
eter (Jasco, Japan) with excitation at 280 nm and emission in the
range of 300−450 nm at a sample concentration of 4 × 10−6 M in a
size-exclusion chromatography (SEC) buffer at 20 °C.
SEC. SEC was performed to estimate the hydrodynamic radius-
based molecular mass of FGF2 and conjugates. The analysis was
carried out at 20 °C using an ÄKTA Explorer FPLC system (GE
Healthcare, UK) with a Superdex 75 HR 10/30 column. Samples at a
concentration of 2.5 mg/mL were loaded onto the column using a full
50 μL loop injection. The mobile phase (25 mM monosodium
phosphate, pH = 7.4; 10 mM Na2SO4) was pumped at a flow rate of 1
mL/min, and the absorption at 280 nm was recorded. Molecular
weight standards containing BPTI, cytochrome C, carbonic
anhydrases, human serum albumin, α-lactoglobulin, chymotrypsino-
gen A, ovalbumin, and albumin were used to generate a standard
curve from which the effective size of the PEGylated conjugates was
estimated.
Dynamic Light Scattering (DLS). DLS experiments were
performed to evaluate the behavior of conjugates in solution.
Measurements were performed using a DynaPro NanoStar instrument
(Wyatt Technology, CA) equipped with a 658 nm (red) laser. A
disposable microcuvette (Wyatt Technology) was used. Each
measurement was performed at 20 °C in the buffer described in the
SEC analysis and it involved 12, 5 s runs. DLS data were collected and
analyzed using DYNAMICS V7 software (Wyatt Technology). All
DLS-based hydrodynamic diameters and molecular masses were
determined by cumulant analysis using the Rayleigh sphere model.
Bio-Layer Interferometry (BLI). To confirm the interaction of
FGF2 after conjugation with extracellular domains of FGFR1, kinetic
rate constants were measured. ForteBio Octet K2 (Pall ForteBio, CA)
and high-precision Streptavidin biosensors (SAX) (Pall ForteBio)
were used. Studies of binding between biotinylated extracellular
domains of FGFR1c fused to Fc fragments and FGF2 or conjugates
were performed in a similar manner to that reported previously.12
Association at different concentrations (40, 60, and 80 nM) was
carried out for 300 s, and the dissociation was monitored for 300 s.
Kinetic parameters were calculated using a 1:1 model with Octet Data
Analysis software 9.0.
Activation of FGF2 Signaling Pathways. We analyzed FGF2-
induced signaling pathways to confirm the ability of FGF2 within
conjugates to perform its primary biological function.12 Briefly, serum-
starved NIH 3T3 cells were incubated for 15 min with 0.1, 1, 5, 10, or
15 ng/mL FGF2 WT, FGF2, or their conjugates in the presence of
heparin (10 U/mL). Then, the whole cell lysate was separated by
sodium dodecyl sulfate−polyacrylamide gel electrophoresis (SDS-
PAGE), transferred onto a PVDF membrane, and analyzed using the
following antibodies: anti-phospho-FGFR, anti-FGFR1, anti-phospho-
p44/42 MAPK, anti-p44/42 MAPK, and anti-γ-tubulin. All primary
antibodies were used at a 1:1000 dilution. Specific protein bands were
visualized with HRP-conjugated secondary antibodies and a
chemiluminescent substrate using a ChemiDoc station (Bio-Rad,
Hercules, CA).
Wide Field Immunofluorescence Microscopy. To test whether
the FGF2 conjugates can be taken up by receptor-mediated
endocytosis in FGFR-expressing cells, we used MCF7 cells stably
expressing FGFR1 (MCF7-R1). The cells, grown on glass coverslips,
were incubated with 300 ng/mL unconjugated FGF2 or FGF2-
(PEG27-MMAE)3 conjugate in the presence of 50 U/mL heparin in
an HEPES medium at 4 °C for 1 h to allow binding of the FGF2
ligands to cell surface receptors. In addition, as an additive control,
MCF7-R1 cells were preincubated on ice with 10-fold excess (3 μg/
mL) of FGF1 before the addition of the FGF2-(PEG27-MMAE)3
conjugate. The cells were then incubated at 37 °C for 40 min to allow
endocytosis and then fixed with 4% formaldehyde in a phosphate-
buffered saline (PBS) buffer. The fixed cells were treated with 0.05%
Saponin for permeabilization and then stained with the following
antibodies: goat anti-FGF2, rabbit anti-FGFR1, and mouse anti-EEA1
and then with the secondary antibodies donkey anti-goat, anti-rabbit,
and anti-mouse coupled to fluorophores Alexa Fluor-488, Alexa Fluor-
568, or Alexa Fluor-647, respectively, and Hoechst33342 for DNA
staining. The stained cells were mounted in a ProLong gold antifade
mountant (Thermo Fisher) and imaged using a DeltaVision OMX V4
microscope (GE Health Care) equipped with an Olympus ×60 NA
1.42 plan apochromat objective, an InsightSSI wide field illumination
module, and three cooled sCMOS cameras. Four-channel (color)
images, including z-stacks covering the entire cell of interest, were
recorded. Raw data images were deconvolved and aligned using
Softworx software (Applied Precision Inc.). For illustrations, a single
z-section (optical section) was selected, and images were prepared
using Fiji software.43
Analysis of the Expression Level of FGFR1 and the
Internalization Efficiency of FGF2 and Its Conjugates. Analysis
of FGFR1 levels in MCF7-R1, MCF7, and DMS114 cell lines was
performed by Western blotting as previously reported.12 Quantifica-
tion of internalization of FGF2 and its conjugates into MCF7-R1 cells
was carried out using flow cytometry and fluorescence microscopy.16
Analysis of the Mechanism of Cell Death. Analysis of the
mechanism of cell death was carried out as previously described.44
Briefly, 100,000 MCF7-R1 cells were seeded into each well of a 12-
well culture plate, allowed to adhere overnight, and treated with 10
nM MMAE or conjugates in the presence of 10 U/mL heparin for 72
h. Then the cells were harvested with a TrypLE Express solution
(Thermo Fisher Scientific), stained by Annexin V-FITC and
propidium iodide (according to the manufacturer’s protocol), and
analyzed by flow cytometry using a NovoCyte 2060R flow cytometer
(ACEA Biosciences, San Diego, CA).
Cell Viability Assay. Conjugate toxicity was quantitatively
measured using the resazurin-based alamarBlue reagent (Thermo
Fisher Scientific, MA). MCF7, MCF7-R1, and DMS114 cells were
seeded in 96-well plates (5000 cells/well) and cultured in the required
media supplemented with 10 U/mL heparin and then treated with
various concentrations of FGF2, conjugates, or unconjugated MMAE.
After 96 h of continuous exposure, the medium was removed and
replaced with a fresh one containing 10% alamarBlue reagent. Then,
after 4 h of incubation, fluorescence emission at 590 nm (excitation at
560 nm) was measured using an EnVision Multilabel Reader
fluorescence plate reader (PerkinElmer, Waltham, MA). Data are
mean values from three independent experiments (each point in a
single experiment was evaluated in triplicate) ± SE. The half-maximal
effective concentration (EC50) was calculated from the concen-
tration−response curve obtained for each preparation.
In Vivo Anti-Cancer Effects of FGF2-(PEG27-MMAE)3 in a
Mouse Xenograft Model. The experimental protocol was evaluated
and approved by the Norwegian Food Safety Authority (FOTSid
8697) and conducted in compliance with the European Convention
of the Protection of Vertebrates Used for Scientific Purposes (EU
Directive 2010/63/EU).
Animal Information. Female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ
(NSG) mice, 3−6 weeks old, were purchased from Jackson
Laboratory (cat. number 005557). The mice were housed according
to the standard regime at the Department of Comparative Medicine,
The Norwegian Radium Hospital, with ad libitum access to food and
water and cage changes twice a week. To ensure tumor growth, 4 μg/
mL beta-estradiol (Sigma-Aldrich, E8875) was added to the drinking
water.
To generate tumors, MCF7-R1 cells (5 × 106) were diluted in 200
μL of serum-free RPMI-1640 media and injected subcutaneously
(s.c.) into the right and left flanks of the mice. After approximately
120 days, MCF7-R1 tumors had reached a volume of about 1000
mm3. The donor mice were then sacrificed by cervical dislocation, and
the MCF7-R1 tumor was extracted and cut into 2 mm3 pieces and s.c.
implanted bilaterally into the flanks of new NSG mice. Anesthesia was
obtained with 4% (v/v) sevofluran (Baxter, Deerfield, IL) along with
1 L/min oxygen and 3 L/min nitrous oxide. After approximately 70
days, the mice were divided into four treatment groups of 4−5 mice,
with an average tumor volume of approximately 100 mm3 in each
group. Each treatment (PBS 10 mL/kg, FGF2 10 mg/kg, MMAE 0.6
mg/kg, and FGF2-(PEG27-MMAE)3 10 mg/kg) was given intra-
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venously (i.v.) in the tail vein once a week for two consecutive weeks.
The tumor volume and the body weight were monitored twice a week
throughout the experiment. The tumor volume was measured using a
caliper, and the volume was calculated as follows: V = W2 × L × 0.5
(where W and L are the shortest and longest tumor diameters,
respectively). To generate the tumor growth curves, the tumor
volume was normalized to the median tumor volume at the beginning
of treatment in each group and plotted over time. Body weights were
normalized to the pretreatment weight. Error bars represent the
standard error of the mean.
Spatial Distribution of Conjugation Sites on the Surface of
FGF2. The structure of FGF2 with an N-terminal extension of
KCKSGG was predicted using the IntFOLD5 server45 and visualized
by UCSF Chimera 1.15 software.46
■ RESULTS AND DISCUSSION
Synthesis of PEGylated MMAE Moieties. Previously, we
reported the ability of FGF2 conjugated to a single MMAE
molecule to kill several cancer cell lines overproducing
fibroblast growth receptor 1.12,13 We also showed that a
drug-to-protein ratio (DPR) of three provided a greater
cytotoxic effect than FGF2 loaded with one or two molecules
of MMAE.12 Wild-type FGF2 has four cysteine residues,
including two buried in the protein core (Cys34 and C101)
and two on the surface (Cys78 and Cys96), exposed to the
solvent and reacting with, for example, maleimide (Figure 1
and Figure S1). Thus, to obtain a DPR of three, we used a
variant of FGF2 with an N-terminal extension of KCKSGG. As
we mentioned previously, the lysine-flanked cysteine residue is
highly susceptible to the maleimide−thiol reaction.11,12
However, the attachment of three highly hydrophobic drug
molecules creates serious problems with aggregation of the
conjugate. In this study, we used a bifunctional PEG
containing an NHS ester and maleimide groups to produce
FGF2 conjugated with three MMAE molecules. In addition to
reducing hydrophobicity, the use of PEG moieties has two
additional advantages: it increases the hydrodynamic radius of
relatively small (17.8 kDa) FGF2 molecules and allows
conjugation of the cytotoxic payload under mild conditions
via two highly reactive groups. In order to investigate the effect
of the PEG size on the hydrodynamic properties of the
Figure 1. Chemical structures of cytotoxic payloads (MMAE and PEGylated MMAEs) and schematic representation of FGF2 conjugates. The
asterisks correspond to the cysteines undergoing conjugation.
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conjugates, we used PEG with either 4 or 27 mers of ethylene
oxide. This yielded two conjugates, each containing three
MMAE molecules with a cathepsin B-sensitive dipeptide (Val-
Cit) linker directly connected to the FGF2 molecule, FGF2-
(PEG4-MMAE)3, and FGF2-(PEG27-MMAE)3 (Figure 1). As
a control, we used previously reported FGF2-MMAE3.
12
We obtained highly homogenous conjugates that contained
almost exclusively triply substituted forms, as shown by SDS-
PAGE, RP-HPLC, and UV−vis (Figure 2A−C). The DPR
values calculated from the UV−vis measurement are 2.9 for
FGF2-MMAE3, 3.1 for FGF2-(PEG4-MMAE)3, and 3.0 for
FGF2-(PEG27-MMAE)3 (Figure 3C).
47 The identity of
conjugates was confirmed by MALDI-MS (Figure 2D and
Table 1).
Biophysical and Biological Properties of the Con-
jugates. To confirm the native state of FGF2 within the
conjugates, we performed fluorescence analysis of the protein
tertiary structure. Properly folded FGF2 exhibits relatively high
emission from tyrosine at around 303 nm and low emission at
353 nm from tryptophan residues, whose emission is quenched
by neighboring residues (Figure 3A). After 2 h of FGF2
unfolding in 3 M guanidine hydrochloride at 80 °C, a huge
increase in fluorescence emission around 353 nm was observed
(Figure 3A). The fluorescence spectra of wild-type FGF2,
unconjugated FGF2 with N-terminal extension (KCKSGG),
and conjugates were similar. They did not show tryptophan
emission, confirming that FGF2 is properly folded after
conjugation with MMAE and PEGylated MMAE (Figure 3A).
The effective hydrodynamic mass of each conjugate was
determined by SEC using a Superdex G75 column (Figure
3B). Compared with the attachment of three MMAE
molecules, the conjugation of three PEG4-MMAE or
PEG27-MMAE molecules increased the hydrodynamic mass
of the conjugate from 16 to 22 kDa and to 34 kDa, respectively
(Figure 3B and Table 1). DLS measurements provided higher
values, from 19 to 24 kDa and 42 kDa, respectively (Figure 3C
and Table 1). We also found that the average hydrodynamic
radius of FGF2-(PEG4-MMAE)3 and FGF2-(PEG27-
MMAE)3 increased to 2.5 and 3 nm in comparison to 2 nm
for FGF2-MMAE3 (Table 1).
To verify whether attachment of three MMAEs via PEG4 or
PEG27 affects the affinity of FGF2 to the extracellular domain
of FGFR1 IIIc, we carried out BLI measurements. For all
molecules tested, the dissociation constant (KD) values were in
the nanomolar range (Table 2). Direct attachment of MMAE
increased the KD value (decreased the affinity to receptor) by a
factor of 4.2. Attachment of MMAE via PEG4 or PEG27 led to
about threefold decrease in affinity.
We also studied whether FGF2 conjugates can activate
FGFR-dependent signaling pathways in NIH 3T3 cells. Serum-
Figure 2. Conjugation of FGF2 to MMAE and PEGylated MMAE. (A) SDS-PAGE analysis of cation exchange-purified conjugation reaction
products. (B) Purity and efficiency of conjugation determined by RP-HPLC. (C) DPR quantified by UV−vis. (D) Mass spectra of FGF2 and
conjugates recorded by MALDI-MS.
Biomacromolecules pubs.acs.org/Biomac Article
https://doi.org/10.1021/acs.biomac.1c00662
Biomacromolecules 2021, 22, 4169−4180
4173
deprived cells were incubated for 15 min with 15 ng/mL FGF2
proteins and FGF2 conjugates. Western blotting analysis of
phospho-FGFR and phospho-ERK 1/2 shows that FGF2
conjugates activated downstream signaling at the same level as
the wild type of FGF2 (Figure 4), indicating that MMAE
conjugated either directly or via PEG4/27 had no effect on the
interaction of FGF2 with its cellular target. To further
investigate whether conjugation does not affect binding of
FGF2 to FGFR1, we examined the activation of downstream
signaling in NIH 3T3 cells at different concentrations of FGF2
conjugates. As shown in Figure S2, for the concentrations
tested (0.1−15 ng/mL), there were no differences in FGFR1
and ERK1/2 phosphorylation between FGF2 WT and FGF2-
based conjugates.
Internalization of FGF2 Conjugates. The cytotoxic
effect of a protein−drug conjugate largely depends on its
efficient receptor-dependent internalization into the cell. As a
first step, we checked FGFR1 levels in MCF7 cells stably
transfected with FGFR1 (MCF7-R1), MCF7, and DMS114
cells by Western blotting analysis of the whole cell lysate. As
shown in Figure 5A, MCF7-R1 cells show a significantly
augmented FGFR1 level compared with DMS114 cells having
a naturally high level of FGFR1 expression. In contrast, the
MCF7 cell line produces trace amounts of FGFR1 (Figure
5A).
Figure 3. Biophysical analysis of FGF2 conjugates. (A) Fluorescence emission spectra (300−450 nm) of FGF2 conjugates at 4 μM concentration
upon excitation at 280 nm. The dashed line represents FGF2 unfolded upon exposure to 80 °C in 3 M GdmCl. (B) Retention volume of FGF2
conjugates determined by SEC. (C) DLS analysis of the protein size distribution. The estimated molecular masses are given in Table 1.
Table 1. Comparison of FGF2 Molecular Masses Calculated
and Determined by MS, SEC, and DLS
molecular mass
calculated MS SEC DLS
preparation [Da] [kDa]
FGF2 17,814.2 17,817.7 17 18
FGF2-MMAE3 21,762.8 21,762.9 16 19
FGF2-(PEG4-MMAE)3 23,322.1 23,332.9 22 24
FGF2-(PEG27-MMAE)3 26,493.4 26,500.5 34 42














× 10−4 [1/s] RMax X2
FGF2 40 0.42 ± 0.01 0.34 7.29 ± 0.06 6.33 3.09 ± 0.06 2.28 0.33 0.0352
60 0.43 ± 0.01 6.56 ± 0.07 2.85 ± 0.07 0.306 0.0414
80 0.18 ± 0.01 5.15 ± 0.03 0.91 ± 0.04 0.3353 0.0135
FGF2-MMAE3 40 1.56 ± 0.02 1.43 2.53 ± 0.01 2.28 3.94 ± 0.06 3.24 0.4331 0.0362
60 1.00 ± 0.03 2.32 ± 0.01 2.33 ± 0.06 0.3591 0.0299
80 1.73 ± 0.02 2.00 ± 0.01 3.46 ± 0.03 0.3951 0.0093
FGF2-(PEG4-
MMAE)3
40 0.65 ± 0.01 0.90 3.65 ± 0.01 2.88 2.38 ± 0.03 2.47 0.5288 0.0236
60 0.83 ± 0.01 2.68 ± 0.01 2.23 ± 0.04 0.5562 0.0301
80 1.21 ± 0.02 2.31 ± 0.01 2.80 ± 0.05 0.5744 0.0498
FGF2-(PEG27-
MMAE)3
40 0.76 ± 0.01 1.08 4.18 ± 0.02 3.34 3.18 ± 0.05 3.41 0.575 0.0489
60 0.97 ± 0.02 3.29 ± 0.02 3.20 ± 0.06 0.5415 0.0697
80 1.52 ± 0.02 2.54 ± 0.01 3.85 ± 0.05 0.5548 0.0555
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Then we analyzed the efficiency of internalization of
fluorescently labeled FGF2 into MCF7-R1, MCF7, and
DMS114 cells by flow cytometry. As shown in Figure 5B,
the highest signal of fluorescently labeled FGF2 was detected
in MCF-R1 cells. A significantly lower signal was observed in
DMS114 cells. Untransfected MCF7 cells displayed weak
fluorescent signals of labeled FGF2. These data correlate with
the FGFR1 levels detected by Western blotting (Figure 5A)
and indicate a strong correlation between the level of receptor
and internalization efficiency.
In the next step, we tested whether the conjugation with
MMAE and PEGylated MMAE affects the efficiency of FGF2
endocytosis. Figure 5C shows the flow cytometry quantifica-
tion of the internalization of FGF2 and its conjugates into
MCF7-R1 cells. We observed that MMAE or PEGylated
MMAE did not influence FGF2 internalization.
Finally, using fluorescence microscopy, we verified that the
FGF2-(PEG27-MMAE)3 conjugate was internalized as effi-
ciently as FGF2 in MCF7 cells stably transfected with FGFR1
(MCF7-R1). To this end, MCF7-R1 cells were incubated with
FGF2 or FGF2-(PEG27-MMAE)3 at 4 °C and next kept at 37
°C for 40 min. Then the cells were fixed and stained by an
antibody against FGF2, FGFR1, and early-endosome antigen 1
(EEA1). Figure 5D shows that both FGF2 and the FGF2-
(PEG27-MMAE)3 conjugate were localized into intracellular
vesicles and most of these vesicles were positive for EEA1, a
membrane-bound marker of early endosomes. Both FGF2 and
the conjugate colocalized with FGFR1. These results indicate
that FGF2-(PEG27-MMAE)3 and FGF2 are efficiently and
specifically endocytosed by an FGFR1-mediated mechanism.
We also tested whether receptor saturation by FGF1 can
block internalization of the conjugate. First, MCF7-R1 cells
were preincubated at 4 °C with a 10-fold excess of FGF1 and
then FGF2-(PEG27-MMAE)3 was added. Cells were then
transferred to 37 °C for 40 min, fixed, and stained as described
above. We did not observe the presence of the FGF2 conjugate
inside the cells (Figure 5D). This experiment supports the
conclusion that FGF2-(PEG27-MMAE)3 is effectively endo-
cytosed in an FGFR1-dependent manner in MCF7-R1 cells as
uptake can be efficiently competed out by the FGFR1 ligand,
FGF1.
In Vitro Cytotoxicity of FGF2 Conjugates. To evaluate
in vitro the inhibitory effects of FGF2 conjugates on cell
growth, we used FGFR1-positive cell lines: DMS 114 (small
cell lung cancer, SCLC)15 and MCF7 (human breast
adenocarcinoma) cells stably transfected with FGFR1
(MCF7-R1). MCF7 cells, expressing a relatively low level of
FGFR1, served as a control cell line.
For FGFR1-positive cells, the conjugates showed a strong
cytotoxic effect. In the case of MCF7-R1 cells, both PEGylated
conjugates (via PEG4 and PEG27) were about twofold more
toxic than the non-PEGylated FGF2-MMAE3. Their cytotox-
icity was comparable to that of free MMAE (Figure 6 and
Table 3). However, for DMS114 cells, all three conjugates
(two PEGylated and FGF2-MMAE3) showed similar EC50
values, in the low nanomolar range, which were about eightfold
lower than those of free MMAE (Figure 6 and Table 3). No
toxic effects of all three conjugates were observed in MCF7
cells. Free MMAE exhibited a high cytotoxic effect at the
subnanomolar level (EC50 = 0.41 nM) (Figure 6 and Table 3).
These results demonstrate high specificity and the potency of
FGF2 conjugates in killing FGFR1-expressing cells.
Furthermore, we examined the mechanism of cell killing by
MMAE and conjugates using the Annexin V−PI assay (Figure
S3). We observed that after 72 h of treatment of MCF7-R1
cells with 10 nM conjugates, the cells were mainly in the early
stage of apoptosis. In the case of free MMAE, the percentage of
early apoptotic cells was lower, in favor of late apoptotic/
necrotic cells. In all treatment groups, the level of viable cells
was at a comparable level (approximately 20%).
FGF2-(PEG27-MMAE)3 Inhibits Tumor Growth In Vivo.
To investigate the anti-tumor effect of FGF2-(PEG27-
MMAE)3 in vivo, MCF7-R1 cells overproducing FGFR1
were injected into the flanks of NSG mice to generate a human
tumor. When tumors reached a size of approximately 100 mm3,
the mice were randomized into the following treatment
groups: vehicle (PBS), empty carrier (FGF2), free MMAE,
or FGF2-(PEG27-MMAE)3 conjugate. The conjugate was
administered once a week for two consecutive weeks at a
concentration of 10 mg/kg body weight, corresponding to a
drug dose of 0.6 mg/kg body weight of free MMAE. Free
auristatin or FGF2 had no effect on the tumor, whereas FGF2-
(PEG27-MMAE)3 very strongly inhibited the tumor growth, as
shown in Figure 7A. Furthermore, it was observed that a higher
dose of free MMAE (1.2 mg/kg) caused a dangerous decrease
in the body weight (Figure S4). Administration of FGF2-
(PEG27-MMAE)3 did not cause any body weight loss or other
side effects in the animals during the treatment period.
However, a reversible weight loss of about 10% was observed
in the mice treated with FGF2 (Figure 7B).
We previously described conjugates of FGF2 with one, two,
or three molecules of hydrophobic vcMMAE, which exhibited
a highly cytotoxic effect against FGFR1-overproducing cell
lines, depending on the number of cytotoxic payloads per
FGF2 molecule. Triply loaded FGF2-vcMMAE showed the
highest cytotoxicity, but due to its increased hydrophobicity, it
tended to precipitate and had to be stored at concentrations
below 1.5 mg/mL.12
In this study, we developed a more hydrophilic version of
FGF2-MMAE3 by introducing a spacer (PEG4 or PEG27)
between FGF2 and vcMMAE, which increased the hydro-
dynamic radius of PEG-containing conjugates and favorably
Figure 4. Activation of downstream signaling in NIH 3T3 cells after
15 min of stimulation with 15 ng/mL FGF2 variants or their
conjugates in the presence of 10 U/mL heparin detected by Western
blotting using anti-phospho-FGFR (pFGFR) and anti-phospho-
ERK1/2 (p-ERK1/2) antibodies. The total amount of FGFR1, ERK
1/2, and γ-tubulin served as loading controls.
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affected the pharmacokinetic properties of the conjugates. In
comparison with non-PEGylated FGF2-MMAE3, the intro-
duction of a small PEG4 linker increased the apparent
molecular mass from 16 to 22 kDa, as determined by SEC
(Figure 3 and Table 1). A much larger increase was found for
the PEG27 spacer (from 16 to 34 kDa) (Figures 2 and 3 and
Table 1). It should be stressed that a similarly large increase in
molecular mass was observed for triply substituted FGF2-
PEG2-MMAE in the DLS analysis. Again, the increase in the
apparent molecular mass for FGF2-(PEG4-MMAE)3 was
much less pronounced. Both SEC and DLS data show that
the size of FGF2-(PEG27-MMAE)3 is sufficient to overcome
renal clearance.48,49 The radius of the FGF2-(PEG27-MMAE)3
conjugate determined by DLS is approximately 3 nm, which
ensures good tumor penetration, in contrast to a full-length
antibody or nanoparticles with radii of 10 and 100 nm,
respectively.50,51 Our observations are consistent with recent
studies of Seattle Genetics company, which showed that the
PEG4 linker is insufficient, whereas PEG chains longer than 8
units improve pharmacokinetics and reduce renal clearance of
ADCs.52 Similarly, Lyon et al. showed that reduced hydro-
phobicity improves pharmacokinetics and expands the
therapeutic windows of ADCs highly loaded with MMAE.53
Furthermore, Simmons et al. showed that the improvement in
PK, tolerability, specificity, and expansion of the therapeutic
window of PEGylated conjugates is mainly due to a reduction
Figure 5. FGFR1 levels and internalization efficiency of FGF2 and its conjugates in MCF7-R1, MCF7, and DMS114 cells. (A) Expression level of
FGFR1 in MCF7-R1, MCF7, and DMS114 cell lines. Equal numbers of cells were separated by SDS-PAGE and subjected to Western blotting
analysis. (B) Flow cytometry analysis of internalization efficiency in MCF7-R1, MCF7, and DMS114 cell lines. Cells were incubated on ice with
500 ng/mL FGF2 labeled with DyLight488 for 60 min. Then cells were moved to 37 °C for 40 min and subsequently analyzed by flow cytometry.
(C) Quantitative analysis of internalization of FGF2 and its conjugates in MCF7-R1 cells. Cells were incubated with FGF2 or its conjugates labeled
with DyLight488 and analyzed by flow cytometry. Data shown are mean fluorescence intensities (MFI) from three independent experiments ±SD.
A one-way ANOVA test was performed, and the differences between groups were statistically insignificant. (D) Fluorescence microscopy analysis of
FGF2 and FGF2-(PEG27-MMAE)3 endocytosis in MCF7-R1 cells. FGF2 (left column) or FGF2-PEG27-MMAE (middle column) were incubated
with cells at 4 °C for 60 min and then at 37 °C for 40 min to allow internalization. Cells shown in the right column were preincubated with FGF1
at 4 °C for 10 min and then incubated with FGF2-(PEG27-MMAE)3 at 4 °C for 60 min before incubation at 37 °C for 40 min. Cells were then
fixed and stained with anti-FGF2 (green), anti-FGFR1 (red), anti-EEA1 (white) antibodies, and Hoechst 33342 to visualize DNA. The squares
marked in the four-color overlay images indicate blown-up regions enlarged and shown in the bottom row. The bar corresponds to 4 μm and to 2
μm in zoomed images.
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in nonspecific interactions.54 Our DLS analysis shows that the
non-PEGylated conjugate has a slightly greater hydrodynamic
radius than FGF2 (1.8 versus 2.2 nm) but migrates more
slowly in the SEC (Figure 3 and Table 1), suggesting that
FGF2-MMAE3, but not its PEGylated variants, makes
nonspecific hydrophobic interactions.
It has been reported that, in several cases, PEG molecules
affect specific interactions of biomolecules with molecular
targets.55,56 In agreement, Zhao et al. observed that
PEGylation of FGF2 at sites located in close proximity to
the receptor-binding region decreased the affinity to the
receptor and heparin and affected its biological activities, such
as activation of downstream signal transduction and
stimulation of proliferation.57 We conjugated PEGylated
drugs to cysteines separated from the primary and secondary
FGFR1 binding sites58 (Figure S1). We validated that PEG4-
and PEG27-based conjugates did not affect the interaction
with isolated extracellular domains of FGFR1 (Table 2) as well
Figure 6. Viability of cells treated with FGF2, FGF2 conjugates, and free MMAE. MCF7-R1, DMS114 (FGFR1-positive), and MCF7 (with low
FGFR1 level) cell lines were treated with the indicated agents for 96 h, and then the cell viability was assessed using the alamarBlue reagent. Data
shown are mean values from three experiments ±SD. Solid lines represent Hill’s equation fits.
Table 3. Cytotoxicity of FGF2 Conjugates and Free MMAE in Different Cell Linesa
preparation
FGF2-MMAE3 FGF2-(PEG4-MMAE)3 FGF2-(PEG27-MMAE)3 MMAE
cell line EC50 [nM]
MCF7 >91★★★ >91★★★ >91★★★ 0.41 ± 0.02
MCF7-R1 1.01 ± 0.42★ 0.59 ± 0.19★ 0.42 ± 0.03★ 0.38 ± 0.05
DMS114 0.09 ± 0.03★★ 0.07 ± 0.01★★ 0.06 ± 0.02★★ 0.54 ± 0.07
aStudent’s t-test was used to determine whether the differences between FGF2-conjugates and free MMAE are statistically significant (p values: ∗,
0.05 > p ≥ 0.01; ∗∗, 0.01 > p ≥ 0.001; ∗∗∗, p < 0.001), n = 3.
Figure 7. Treatment efficacy and toxicity in mice bearing MCF7-R1 tumors. NSG mice (four mice per group) were treated once a week for two
consecutive weeks (day 0 and 7) with intravenous injections of 10 mL/kg PBS, 10 mg/kg FGF2, 0.6 mg/kg MMAE, and 10 mg/kg FGF2-(PEG27-
MMAE)3, (A) growth inhibitory effect measured as relative tumor volume. (B) Relative body weight of the treated mice. Error bars represent the
standard error of the mean. The arrows indicate the day of administration of the preparations, and the dashed line shows the safe level of weight
loss. A Student’s t-test was used to determine the statistical significance (p values: ∗, 0.05 > p ≥ 0.01).
Biomacromolecules pubs.acs.org/Biomac Article
https://doi.org/10.1021/acs.biomac.1c00662
Biomacromolecules 2021, 22, 4169−4180
4177
as FGFR1 on the surface of NIH 3T3 cells (Figure 4 and
Figure S2).
Proper interaction of the conjugates with FGF receptors
ensures efficient internalization and FGFR-dependent traffick-
ing to endosomes and then lysosomes, which is crucial for
MMAE release and cell-killing effect32,59,60 As shown in Figure
5, all conjugates were internalized at the same level as FGF2.
Both FGF2 and FGF2-(PEG27-MMAE)3 were internalized
into the cell interior and colocalized with FGFR1 in
endosomes. Furthermore, after cell surface saturation with
FGF1, no internalization of FGF2-PEG27-MMAE3 was
observed (Figure 5D right column), further ruling out an
FGFR1-independent pathway of conjugate endocytosis. This is
very important since MMAE equipped with a Val-Cit dipeptide
and a PAB spacer requires lysosome-associated cathepsin B to
release the active form of cytotoxin.61
Both FGF2-(PEG4-MMAE)3 and FGF2-(PEG27-MMAE)3
exhibited high cytotoxicity against FGFR1-positive cell lines
(DMS114 and MCF7-R1) in in vitro assays (EC50 values from
subnanomolar to nanomolar range) and were nontoxic to the
FGFR1-negative cell line (MCF7) (Figure 6 and Table 3). The
DMS114 cell line showed the highest sensibility to the
conjugates, with no significant differences between PEG4- and
PEG27-based conjugates. These conjugates were at least six
times more toxic than free MMAE (Figure 6 and Table 3). In
the case of the MCF7-R1 cell line, introduction of the PEG27
linker resulted in approximately twofold higher cytotoxicity
(FGF2-MMAE3 versus FGF2-(PEG27-MMAE)3) (Figure 6
and Table 3). Furthermore, we showed that FGF2-based
conjugates induce death mainly via apoptosis rather than
necrosis or other mechanisms (Figure S3).
Finally, we show that administration of the FGF2-(PEG27-
MMAE)3 conjugate at a dose of 10 mg/kg on day 0 and a
second equal dose on day 7 resulted in a noticeable reduction
in the tumor volume. On day 13, the relative tumor volume in
the conjugate-treated group had decreased to 58% of the initial
size. Further reduction in the tumor volume was not observed,
but tumor growth was stunted. Administration of free MMAE
in contrast to the FGF2-PEG27-MMAE3 conjugate did not
inhibit tumor growth. Moreover, FGF2-PEG27-MMAE3 did
not significantly affect the body weight of mice (Figure 7B),
which supports the efficacy of PEGylated FGF2 conjugates as
an anti-cancer agent targeting tumors with FGFR1 over-
production.
■ CONCLUSIONS
We show for the first time the effect of an FGF2-based
conjugate on the growth of the human breast cancer cell line
MCF7-R1, overexpressing FGFR1, which is grown as a
xenograft in NSG mice. So far, only one ADC (Aprutumab
Ixadotin, BAY 1187982) targeting the FGF receptor (FGFR2)
has been tested in phase I clinical trials, but it was poorly
tolerated by patients and is, consequently, no longer under
consideration.62 The promising data presented in this study
show that our FGF2-based PEGylated conjugate should be
further developed for targeting FGFR1-positive tumors.
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